Agenda

 

 

SAN DIEGO, 28 November 2022 - 1 December 2022

Schedule

Create your personal agenda –check the favourite icon

Nov 298:30
Conference pass

Opening keynote presentation: Integrated Pandemic Preparedness

Keynotes
  • How vaccines, monoclonals, direct acting antiviral, agents targeting host factors have essential roles in mounting a broad, response to future pandemics
  • The need to develop and validate assays for detection of infection and measurement of immunity
Nov 299:00
Conference pass

Panel: HIV – how can we end the epidemic?

Keynotes
  • How is new research bringing the goal of a cure within reach?
  • HIV Vaccine, antibody, and antiviral landscape
  • Merits / potential of different approaches – mRNA, bNAbs, LAAV, pre-exposure prophylaxis, prophylactic vs therapeutic vaccines
    • How are we def
  • To achieve success must reach all those disproportionately affected - How can PPP help to achieve this?
Nov 2910:00
Conference pass

Defining immune fitness / immune health and its implications for ID & Cancer

Keynotes
  • How do we define immune fitness / immune health – progress towards human immunome
  • How are we studying this at a systems level?
  • How do vaccines positively impact immune fitness?
  • Defining tumor archetypes – what common immunological features contribute to better response rates
Nov 2911:00
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 2911:45
Conference pass

How can partnering with federal labs help your business?

Interactive Roundtables
Nov 2911:45
Conference pass

How can we utilize mRNA technology to develop next generation therapeutics?

Interactive Roundtables
Ariel Weinberger, Chief Executive Officer, Autonomous
Nov 2911:45
Conference pass

How to effectively tailor prevention and treatment strategies to pediatric populations?

Interactive Roundtables
Dr Barbara Rath, Co-founder & Chair, Vienna Vaccine Safety Initiative; Chair, ISIRV Epi Group, Board Member, ISIRV & ESCMID/ESGREV, Vienna Vaccine Safety Initiative
Nov 2911:45
Conference pass

The future of vaccine trial sites post-COVID

Interactive Roundtables
Nov 2912:30
Conference pass

Exhibition & Partnering Break

Keynotes
  • Lunch served in exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 2913:50
Conference pass

Safety & efficacy updates of Janssen COVID-19 vaccine

WVIC - ID Vaccines
Nov 2913:50
Conference pass

Panel: Understanding the TME; what’s left to learn

WVIC - Immune Monitoring
  • Systems biology approaches to studying the TME – what have we learnt that we didn’t know before?
  • How can we apply proteomics to the TME – how is this informing multiple targets?
Nov 2913:50
Conference pass

The Centers for Research in Emerging Infectious Diseases (CREID) Network: Research Integrated Surveillance and Monitoring

WAC - Emerging & Reemerging Diseases
Nov 2914:20
Conference pass

Oral COVID-19 vaccine ph II trials

WVIC - ID Vaccines
Nov 2914:20
Conference pass
Nov 2914:20
Conference pass

Applying machine learning for antiviral drug discovery

WAC - Emerging & Reemerging Diseases
Nov 2914:50
Conference pass

SARS-CoV-2 Vaccine design to broaden effector immune responses

WVIC - ID Vaccines
Nov 2914:50
Conference pass

Progress of therapies to overcome suppression in the TME

WVIC - Immune Monitoring
Nov 2914:50
Conference pass

Using nanocrystal prodrugs as ultra-long-acting chemical treatment for HIV

WAC - HIV
Dr Howard Gendelman, Co-founder, Exavir Therapeutics
Nov 2914:50
Conference pass

Targeted Protein Degradation–A novel approach to combat viral pathogens

WAC - Emerging & Reemerging Diseases
Dr Priscilla Yang, Professor, Stanford University School of Medicine (USA)
Nov 2915:05
Conference pass

A new vaccine platform for emerging virus threats such as SARS-2, HIV, and RSV

WVIC - ID Vaccines
Nov 2915:20
Conference pass

Glycoconjugate approaches for evoking antibodies to sugars on HIV-1

WAC - HIV
Nov 2915:20
Conference pass

Fleximers–using unique nucleosides as a flexible approach to antiviral treatment

WAC - Emerging & Reemerging Diseases
Nov 2915:50
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 2916:20
Conference pass

Novel Checkpoint Inhibitor Combination Vaccines (PD-1, PD-L1, CTLA-4, TIGIT, LAG3)

WVIC - Cancer Immunotherapy
Nov 2916:20
Conference pass

Preventing HIV Drug Resistance to Current and Future Antiretroviral Treatment Regimens

WAC - HIV
Dr Robert Shafer, Professor of Medicine-Infectious Diseases, Stanford University School of Medicine (USA)
Nov 2916:20
Conference pass

Tackling Marburg virus strains with humanized mAbs

WAC - Emerging & Reemerging Diseases
Nov 2916:50
Conference pass
Nov 2916:50
Conference pass

A novel platform for early diagnosis & predicting responses to immune checkpoint inhibitor treatment

WVIC - Immune Monitoring
Nov 2916:50
Conference pass

Versamune t-cell activating platform for HPV related cancers

WVIC - Cancer Immunotherapy
Nov 2916:50
Conference pass

Are long-acting ARTs the future of HIV prevention and treatment?

WAC - HIV
  • How can we improve the half-life of long-acting ARTs?
  • How can we enhance the uptake/usage of long-acting formulations?
  • What are the implementation challenges for therapies?
  • What are the key policy issues for these types of therapies?
  • Why can long-acting injectable therapies be difficult to access in LMIC?
Nov 2916:50
Conference pass

A repurposing antiviral solution for the prevention and treatment of Dengue

WAC - Emerging & Reemerging Diseases
David Foster, Chief Executive Officer, Island Pharmaceuticals
Nov 2917:20
Conference pass

7HP349, an integrin agonist to overcome resistance to immune checkpoint blockade

WVIC - Cancer Immunotherapy
Nov 2917:20
Conference pass

Structural mapping of the humoral immune response to the Lassa virus glycoprotein

WAC - Emerging & Reemerging Diseases
Nov 2917:35
Conference pass

Studies informing mechanisms of resistance in oncology

WVIC - Immune Monitoring
Nov 2917:35
Conference pass

Developing an antiviral solution for Zika

WAC - Emerging & Reemerging Diseases

Create your personal agenda –check the favourite icon

Nov 309:00
Conference pass

Global Health Goals – can we get back on track?

WVIC - Plenary
  • How has the pandemic affected the status of the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases?
  • GSK - Focus on malaria (inc. salmonela / shigella?) – how will malaria vaccines be implemented?
  • HDT - TB and what went wrong? Next steps for TB vaccines.
  • Partnerships to achieve these goals
Nov 309:10
Conference pass

Panel: What is the future of COVID-19 therapeutics?

WAC - Plenary
  • What are the key areas of focus for 2023 and onwards?
  • What novel therapies are being investigated?
  • Is there a particular part of the SARS-CoV-2 infection cycle being targeted?
  • Is there a silver bullet out there and what would it look like?
  • How to ensure therapeutic interventions are easily accessible?
  • How will the current and future COVID-19 therapeutics be used in the case of a new outbreak?
Dr Robert Jordan, Senior Program Officer, Bill & Melinda Gates Foundation
Pei-Yong Shi, Kempner Professor Of Human Genetics, University of Texas Medical Branch
Meghan Pennini, Director of Therapeutics H-CORE, HHS
Dr Jay Grobler, Associate Vice President Infectious Disease and Vaccines, Merck And Company
Nov 3010:00
Conference pass

Challenges & opportunities in moving immuno-oncology drugs into earlier stages

WVIC - Plenary
  • What are the challenges that need to be overcome before we can move immunotherapies into earlier stages?
  • What is effect of moving earlier in moving into adjuvant/neoadjuvant space? The need to understand progression much earlier in disease.
  • What are our current assumptions – what data do we need to pressure test them? How do we collect data? What data do we need?
Nov 3010:00
Conference pass

Panel: Overcoming obstacles in developing therapeutics for neglected and emerging diseases

WAC - Plenary
  • What are the challenges in designing effective clinical trials for these diseases?
  • What role do platform trials play?
  • What are the key regulatory issues?
  • How would a collaborative nature between researchers and regulatory help with development?
  • Why is funding an issue? What can be done to combat this issue?
  • How to react most efficiently to unexpected disease surges (e.g Monkeypox outbreak)
Mara Kreishman-Deitrick, Deputy Commander, United States Army Medical Material Development Activity
Nancy Sullivan, Senior Investigator and Chief of the Biodefense Research Section, NIH
Dr Phil Gomez, Chief Executive Officer, SIGA Technologies, Inc.
Nov 3011:00
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 3011:40
Conference pass

Panel: Research & development goals for influenza vaccines

WVIC - ID Vaccines
  • What is the status of the influenza vaccine R&D landscape?
  • What areas of R&D are we focusing on to improve influenza vaccines?
  • Strategic goals for seasonal vs universal flu vaccines
  • Recent milestones achieved and gaps to address
  • What tools do we need to inform policy, and preparedness planning?
  • Pivoting to new manufacturing platforms to ensure faster response – what are the challenges
Nov 3011:40
Conference pass

Recent studies informing our understanding of SARS-CoV-2 Immunity * Title TBC

WVIC - Immune Monitoring
Nov 3011:40
Conference pass
Nov 3011:55
Conference pass

SARS-CoV-2 Biology and Countermeasure Development

WAC - COVID-19
Pei-Yong Shi, Kempner Professor Of Human Genetics, University of Texas Medical Branch
Nov 3011:55
Conference pass

AI driven automated viral infectivity assay to expedite antiviral drug discovery

WAC - Delivery & Technology
Nov 3012:10
Conference pass

Personal dendritic cell vaccines for cancer and covid-19

WVIC - Cancer Immunotherapy
Nov 3012:10
Conference pass

Structure-based drug design against SARS-CoV-2 main protease using X-rays, neutrons and computation

WAC - COVID-19
Nov 3012:10
Conference pass

Pathological modeling and control system for optimizing antivirals for COVID-19 and beyond

WAC - Delivery & Technology
Nov 3012:40
Conference pass

Invariable regions – a better universal flu target

WVIC - ID Vaccines
Nov 3012:40
Conference pass

Individualized Neoantigen Immunotherapy in early stage and advanced solid tumors

WVIC - Cancer Immunotherapy
Nov 3012:40
Conference pass

Development of fully human monoclonal antibodies against SARS-CoV2 using peripheral B-cells from COVID-19 survivors

WAC - COVID-19
Nov 3013:10
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 3014:30
Conference pass

Showcase 1: Driven by personal experience: Discovery and development of broad-spectrum antiviral agents against respiratory track viruses

WAC - COVID-19
Nov 3014:45
Conference pass

Showcase 2: Next generation RNAi therapy to treat COVID-19 and other respiratory diseases

WAC - COVID-19
Nov 3014:45
Conference pass

Inhaled IFN-β (SNG001) for the treatment of COVID-19 and other severe viral lung infections

WAC - Delivery & Technology
Phillip Monk, Chief Scientific Officer, Synairgen Research Ltd
Nov 3015:00
Conference pass

Showcase 3: Rapid virus clearance by a novel 3CL protease inhibitor in treatment of COVID-19

WAC - COVID-19
Nov 3015:30
Conference pass

LUNAR – Flu & Covid-19 Vaccines

WVIC - ID Vaccines
Nov 3015:30
Conference pass

Enhancing delivery via Thin Film Freezing technology for inhalable antivirals

WAC - Delivery & Technology
Nov 3015:45
Conference pass

Showcase 6: Broadly acting cathepsins inhibitor against omicron and other variants of concern

WAC - COVID-19
Nov 3016:00
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 3016:30
Conference pass

Developing broad-spectrum influenza vaccines against pandemic threats

WVIC - ID Vaccines
Nov 3016:30
Conference pass

Plug-and-play nanoparticle vaccine platform to target HIV, RSV, Ebola and SARs-CoV-2

WVIC - Immune Monitoring
Nov 3016:30
Conference pass

Treating COVID-19 in Pregnancy – The COVID-19 International Drug Pregnancy Registry (COVID-PR)

WAC - COVID-19
Nov 3017:00
Conference pass

Pandemic Antiviral Discovery (PAD) initiative–Catalysing antiviral discovery and development

WAC - COVID-19
Dr Robert Jordan, Senior Program Officer, Bill & Melinda Gates Foundation
Nov 3017:00
Conference pass

Cellular Nanosponges as an Emerging Antiviral Technology

WAC - Delivery & Technology

Create your personal agenda –check the favourite icon

Dec 19:30
Conference pass

Accelerating innovation –leveraging partnerships and collaborations to advance solutions to ID & Cancer

WVIC - Plenary
  • What are the advantages of partnering with big pharma, federal labs, accelerators, foundations and private investors?
  • What are their programmatic interests of the players involved in getting technologies to market?
  • What emerging technologies are those in charge of partnering and collaboration most excited about?
  • How can you position yourself optimally to get your tech noticed?
Dec 19:30
Conference pass

Panel: Therapeutic approaches to pandemic preparedness

WAC - Plenary
  • Prediction–Predicting the next viral threat and developing a drug with a specific target
  • Broad-spectrum–Developing drugs that work broadly across many stains/viruses
  • Platforms–Warp speed platforms to develop therapeutics once a threat appears
  • What are the advantages and disadvantages of each approach?
Dec 110:30
Conference pass

BRUNCH - Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Dec 111:30
Conference pass

Chair’s opening remarks

WAC - Hepatitis
Dec 111:40
Conference pass

Development of two vaccine candidates implementing proprietary protective antigens against Streptococcus pneumoniae (MVX01) and Clostridioides difficile (MVX02)

WVIC - ID Vaccines
Dec 111:40
Conference pass

How can an Intellectual Property International Consortium (IPIC) benefit small biotechs?

WVIC - New Technology
Dec 111:40
Conference pass

Developing immune cell ligands as a treatment strategy for Influenza

WAC - Respiratory Viruses
Dec 111:55
Conference pass

Bacterial structural vaccinology and novel target delivery

WVIC - ID Vaccines
Dec 111:55
Conference pass

How are investors thinking about biopharma stocks?

WVIC - New Technology
Dec 112:10
Conference pass

B-Tech vector platform for development of next gen Pertussis and TB vaccines

WVIC - ID Vaccines
Dec 112:10
Conference pass

Showcase 1: A new approach to therapeutic cancer vaccines

WVIC - New Technology
Dec 112:10
Conference pass

Novel broad-spectrum influenza A PB2 inhibitor: clinical update

WAC - Respiratory Viruses
Dec 112:25
Conference pass

Progress towards GAS and Periodontitis vaccines

WVIC - ID Vaccines
Dec 112:25
Conference pass

Showcase 2: Early development of Smallpox & Monkey Pox Vaccines

WVIC - New Technology
Dec 112:40
Conference pass

Neutralizing Staphylococcus aureus virulence for vaccination and immunotherapy

WVIC - ID Vaccines
Dec 112:40
Conference pass

Subviral particle clearance and transaminase flares – roles in functional cure.

WAC - Hepatitis
Dec 113:00
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Dec 113:30
Conference pass

The role of influenza antivirals–How can we reduce morbidity and mortality at the individual and population level?

WAC - Respiratory Viruses
Dec 113:30
Conference pass

Protocol Interferon Lambda–First oral Antiviral for Hepatitis D

WAC - Hepatitis
Dec 113:45
Conference pass

Showcase 5: Engineering a novel SARS-CoV2 B-cell epitope vaccine and investigation in transgenic K18-hACE2 mice

WVIC - New Technology
Dec 114:30
Conference pass

Joint Closing Keynote Plenary Session - Leveraging genetic insights to identify novel targets for immune-based diseases

Keynotes
  • How are data driven approaches being used for vaccine discovery / novel drugs in oncology?
last published: 03/Aug/22 12:15 GMT

For conference programme and speaking opportunities:
Lauren Sheppard

lauren.sheppard@terrapinn.com

For sponsorship and exhibition opportunities:
Thomas Hall

thomas.hall@terrapinn.com